vs
ARROWHEAD PHARMACEUTICALS, INC.(ARWR)与STURM RUGER & CO INC(RGR)财务数据对比。点击上方公司名可切换其他公司
ARROWHEAD PHARMACEUTICALS, INC.的季度营收约是STURM RUGER & CO INC的1.7倍($264.0M vs $151.1M),ARROWHEAD PHARMACEUTICALS, INC.同比增速更快(10461.3% vs 3.6%),STURM RUGER & CO INC自由现金流更多($12.3M vs $11.3M)
Arrowhead Pharmaceuticals是总部位于美国加利福尼亚州帕萨迪纳的上市生物制药企业,专注于通过RNA干扰(RNAi)作用机制开发创新药物,核心研发管线覆盖乙型肝炎、α-1抗胰蛋白酶缺陷相关肝病及心血管疾病的治疗领域。
鲁格公司(Ruger)是总部位于美国康涅狄格州绍斯波特的枪械制造企业,除总部外,还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立,自1969年起公开上市交易。
ARWR vs RGR — 直观对比
营收规模更大
ARWR
是对方的1.7倍
$151.1M
营收增速更快
ARWR
高出10457.7%
3.6%
自由现金流更多
RGR
多$1.0M
$11.3M
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $264.0M | $151.1M |
| 净利润 | $30.8M | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | 15.5% | 2.3% |
| 净利率 | 11.7% | — |
| 营收同比 | 10461.3% | 3.6% |
| 净利润同比 | 117.8% | — |
| 每股收益(稀释后) | $0.22 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
ARWR
RGR
| Q4 25 | $264.0M | $151.1M | ||
| Q3 25 | — | $126.8M | ||
| Q2 25 | — | $132.5M | ||
| Q1 25 | — | $135.7M | ||
| Q4 24 | — | $145.8M | ||
| Q3 24 | — | $122.3M | ||
| Q2 24 | — | $130.8M | ||
| Q1 24 | — | $136.8M |
净利润
ARWR
RGR
| Q4 25 | $30.8M | — | ||
| Q3 25 | — | $1.6M | ||
| Q2 25 | — | $-17.2M | ||
| Q1 25 | — | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | — | $7.1M |
毛利率
ARWR
RGR
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
营业利润率
ARWR
RGR
| Q4 25 | 15.5% | 2.3% | ||
| Q3 25 | — | -2.7% | ||
| Q2 25 | — | -15.6% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | — | 5.5% |
净利率
ARWR
RGR
| Q4 25 | 11.7% | — | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | -13.0% | ||
| Q1 25 | — | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 5.2% |
每股收益(稀释后)
ARWR
RGR
| Q4 25 | $0.22 | $0.22 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | — | $-1.05 | ||
| Q1 25 | — | $0.46 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | — | $0.47 | ||
| Q1 24 | — | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $715.0M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $568.4M | $283.8M |
| 总资产 | $1.6B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
ARWR
RGR
| Q4 25 | $715.0M | $92.5M | ||
| Q3 25 | — | $80.8M | ||
| Q2 25 | — | $101.4M | ||
| Q1 25 | — | $108.3M | ||
| Q4 24 | — | $105.5M | ||
| Q3 24 | — | $96.0M | ||
| Q2 24 | — | $105.6M | ||
| Q1 24 | — | $115.3M |
股东权益
ARWR
RGR
| Q4 25 | $568.4M | $283.8M | ||
| Q3 25 | — | $279.6M | ||
| Q2 25 | — | $289.3M | ||
| Q1 25 | — | $321.5M | ||
| Q4 24 | — | $319.6M | ||
| Q3 24 | — | $314.9M | ||
| Q2 24 | — | $321.5M | ||
| Q1 24 | — | $332.0M |
总资产
ARWR
RGR
| Q4 25 | $1.6B | $342.0M | ||
| Q3 25 | — | $342.3M | ||
| Q2 25 | — | $349.5M | ||
| Q1 25 | — | $379.0M | ||
| Q4 24 | — | $384.0M | ||
| Q3 24 | — | $373.5M | ||
| Q2 24 | — | $376.7M | ||
| Q1 24 | — | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $13.5M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $11.3M | $12.3M |
| 自由现金流率自由现金流/营收 | 4.3% | 8.2% |
| 资本支出强度资本支出/营收 | 0.8% | 2.1% |
| 现金转化率经营现金流/净利润 | 0.44× | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势,按日历期对齐
经营现金流
ARWR
RGR
| Q4 25 | $13.5M | $15.5M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | — | $14.7M | ||
| Q1 25 | — | $11.1M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | — | $7.3M |
自由现金流
ARWR
RGR
| Q4 25 | $11.3M | $12.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
自由现金流率
ARWR
RGR
| Q4 25 | 4.3% | 8.2% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
资本支出强度
ARWR
RGR
| Q4 25 | 0.8% | 2.1% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 1.3% |
现金转化率
ARWR
RGR
| Q4 25 | 0.44× | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARWR
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |